{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:06Z","timestamp":1707525606178},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"DOI":"10.7759\/cureus.51860","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:51:25Z","timestamp":1704721885000},"source":"Crossref","is-referenced-by-count":0,"title":["Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Entity in Clinical Practice"],"prefix":"10.7759","author":[{"given":"B\u00e1rbara","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470406","article-title":"High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma","volume":"47","author":"Adachi M","year":"1994","unstructured":"Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, Yachi A. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994, 47:278-82. 10.1002\/ajh.2830470406","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1309\/FY6PK436NBK0RYD4","article-title":"CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells","volume":"127","author":"Herling M","year":"2007","unstructured":"Herling M, Jones D. CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007, 127:687-700. 10.1309\/FY6PK436NBK0RYD4","journal-title":"Am J Clin Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard J","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, et al.. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002, 99:1556-63. 10.1182\/blood.v99.5.1556","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors","article-title":"The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors","author":"Li W","year":"2022","unstructured":"Li W. The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors. Leukemia [Internet]. Leukemia (ed): Exon Publications, Brisbane (AU); 2022. 10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3259","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"12","author":"Zhang YW","year":"2016","unstructured":"Zhang YW, Zhong JH, Chen XL, Xiao F, Chen FY. Blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Exp Ther Med. 2016, 12:319-22. 10.3892\/etm.2016.3259","journal-title":"Exp Ther Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano L","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, et al.. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013, 98:239-46. 10.3324\/haematol.2012.072645","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050595","article-title":"Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects","volume":"11","author":"Sapienza MR","year":"2019","unstructured":"Sapienza MR, Pileri A, Derenzini E, et al.. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers (Basel). 2019, 11:595. 10.3390\/cancers11050595","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano L","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016, 174:188-202. 10.1111\/bjh.14146","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou F","year":"2019","unstructured":"Garnache-Ottou F, Vidal C, Biichl\u00e9 S, et al.. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Adv. 2019, 3:4238-51. 10.1182\/bloodadvances.2019000647","journal-title":"Blood Adv"},{"key":"ref10","article-title":"Blastic plasmacytoid dendritic cell neoplasm","author":"Singh A","year":"2022","unstructured":"Singh A, Singh D. Blastic plasmacytoid dendritic cell neoplasm. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju N","year":"2022","unstructured":"Pemmaraju N, Wilson NR, Garcia-Manero G, et al.. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022, 6:3027-35. 10.1182\/bloodadvances.2021006645","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/214584-blastic-plasmacytoid-dendritic-cell-neoplasm-a-rare-entity-in-clinical-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:38Z","timestamp":1707509678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/214584-blastic-plasmacytoid-dendritic-cell-neoplasm-a-rare-entity-in-clinical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.51860","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}